Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade?
Acta Haematologica · 2024 · 147 (1) · 99-112
DOI: 10.1159/000534341 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Haematologica, online erschienen am 09.10.2023. Verfasst von Ofrat Beyar Katz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous B-cell malignancy, affecting mainly older adults. Despite the recent introduction of multiple targeted agents, CLL remains an incurable disease. Cellular therapy is a promptly evolving area that has developed over the last decades from such standard of care as hematopoietic cell transplantation (HCT) to the novel treatment modalities employing genetically engineered immune cells. Summary: Tailoring the proper treatment for each patient is warranted and should take into account the disease biology, patient characteristics, and the available treatment modalities. Nowadays, the most broadly applied cellular therapies for CLL management are HCT and chimeric antigen receptor-T (CAR-T) cells. However, CAR-T cell therapy is currently not yet approved in CLL, and the appropriate sequencing for the administration of these agents remains to be clarified. Key Messages: The current review will discuss various available cellular treatment options, their advances and limitations, as well as the optimal timing for the employment of such therapies in CLL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Zitieren
APA
Katz, O. B., Yehudai-Ofir, D., & Zuckerman, T. (2024). Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade?. Acta Haematologica, 147(1), 99-112. https://doi.org/10.1159/000534341
Vancouver
Katz OB, Yehudai-Ofir D, Zuckerman T. Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade?. Acta Haematologica. 2024;147(1):99-112. doi:10.1159/000534341
BibTeX
@article{Katz2024,
author = {Katz, Ofrat Beyar and Yehudai-Ofir, Dana and Zuckerman, Tsila},
title = {Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade?},
journal = {Acta Haematologica},
year = {2024},
volume = {147},
number = {1},
pages = {99--112},
doi = {10.1159/000534341}
}
EUVIMED